BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 30867224)

  • 1. Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes.
    Jabbari E; Woodside J; Guo T; Magdalinou NK; Chelban V; Athauda D; Lees AJ; Foltynie T; Houlden H; Church A; Hu MT; Rowe JB; Zetterberg H; Morris HR
    J Neurol Neurosurg Psychiatry; 2019 Jul; 90(7):768-773. PubMed ID: 30867224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes.
    Magdalinou NK; Paterson RW; Schott JM; Fox NC; Mummery C; Blennow K; Bhatia K; Morris HR; Giunti P; Warner TT; de Silva R; Lees AJ; Zetterberg H
    J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1240-7. PubMed ID: 25589779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms.
    Santaella A; Kuiperij HB; van Rumund A; Esselink RAJ; van Gool AJ; Bloem BR; Verbeek MM
    BMC Neurol; 2020 Jan; 20(1):26. PubMed ID: 31952511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson's disease.
    Paslawski W; Khosousi S; Hertz E; Markaki I; Boxer A; Svenningsson P
    Transl Neurodegener; 2023 Sep; 12(1):42. PubMed ID: 37667404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid NFL in the differential diagnosis of parkinsonian disorders: A meta-analysis.
    Ge F; Ding J; Liu Y; Lin H; Chang T
    Neurosci Lett; 2018 Oct; 685():35-41. PubMed ID: 30036569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct Lysosomal Network Protein Profiles in Parkinsonian Syndrome Cerebrospinal Fluid.
    Boman A; Svensson S; Boxer A; Rojas JC; Seeley WW; Karydas A; Miller B; Kågedal K; Svenningsson P
    J Parkinsons Dis; 2016 Apr; 6(2):307-15. PubMed ID: 27061067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics.
    Magdalinou NK; Noyce AJ; Pinto R; Lindstrom E; Holmén-Larsson J; Holtta M; Blennow K; Morris HR; Skillbäck T; Warner TT; Lees AJ; Pike I; Ward M; Zetterberg H; Gobom J
    Parkinsonism Relat Disord; 2017 Apr; 37():65-71. PubMed ID: 28214264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-Synuclein Protofibrils in Cerebrospinal Fluid: A Potential Biomarker for Parkinson's Disease.
    von Euler Chelpin M; Söderberg L; Fälting J; Möller C; Giorgetti M; Constantinescu R; Blennow K; Zetterberg H; Höglund K
    J Parkinsons Dis; 2020; 10(4):1429-1442. PubMed ID: 33016895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders.
    Mondello S; Constantinescu R; Zetterberg H; Andreasson U; Holmberg B; Jeromin A
    Parkinsonism Relat Disord; 2014 Apr; 20(4):382-7. PubMed ID: 24507721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson's disease from atypical parkinsonism: Evidence from a meta-analysis.
    Sako W; Murakami N; Izumi Y; Kaji R
    J Neurol Sci; 2015 May; 352(1-2):84-7. PubMed ID: 25868897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid neurofilament light and tau protein as mortality biomarkers in parkinsonism.
    Constantinescu R; Rosengren L; Eriksson B; Blennow K; Axelsson M
    Acta Neurol Scand; 2019 Aug; 140(2):147-156. PubMed ID: 31070772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
    Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
    Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
    Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
    JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurofilament heavy-chain NfH(SMI35) in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes.
    Brettschneider J; Petzold A; Süssmuth SD; Landwehrmeyer GB; Ludolph AC; Kassubek J; Tumani H
    Mov Disord; 2006 Dec; 21(12):2224-7. PubMed ID: 17013909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oligomeric α-synuclein and tau aggregates in NDEVs differentiate Parkinson's disease from atypical parkinsonisms.
    Meloni M; Agliardi C; Guerini FR; Zanzottera M; Bolognesi E; Picciolini S; Marano M; Magliozzi A; Di Fonzo A; Arighi A; Fenoglio C; Franco G; Arienti F; Saibene FL; Navarro J; Clerici M
    Neurobiol Dis; 2023 Jan; 176():105947. PubMed ID: 36481435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders.
    Constantinescu R; Rosengren L; Johnels B; Zetterberg H; Holmberg B
    Parkinsonism Relat Disord; 2010 Feb; 16(2):142-5. PubMed ID: 19647470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The biomarker potential of cell-free microRNA from cerebrospinal fluid in Parkinsonian Syndromes.
    Starhof C; Hejl AM; Heegaard NHH; Carlsen AL; Burton M; Lilje B; Winge K
    Mov Disord; 2019 Feb; 34(2):246-254. PubMed ID: 30557454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal Fluid Levels of 5-Hydroxyindoleacetic Acid in Parkinson's Disease and Atypical Parkinsonian Syndromes.
    Kaiserova M; Chudackova M; Prikrylova Vranova H; Mensikova K; Kastelikova A; Stejskal D; Kanovsky P
    Neurodegener Dis; 2021; 21(1-2):30-35. PubMed ID: 34695830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder.
    Hansson O; Janelidze S; Hall S; Magdalinou N; Lees AJ; Andreasson U; Norgren N; Linder J; Forsgren L; Constantinescu R; Zetterberg H; Blennow K;
    Neurology; 2017 Mar; 88(10):930-937. PubMed ID: 28179466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined CSF α-SYN RT-QuIC, CSF NFL and midbrain-pons planimetry in degenerative parkinsonisms: From bedside to bench, and back again.
    Compta Y; Painous C; Soto M; Pulido-Salgado M; Fernández M; Camara A; Sánchez V; Bargalló N; Caballol N; Pont-Sunyer C; Buongiorno M; Martin N; Basora M; Tio M; Giraldo DM; Pérez-Soriano A; Zaro I; Muñoz E; Martí MJ; Valldeoriola F
    Parkinsonism Relat Disord; 2022 Jun; 99():33-41. PubMed ID: 35594661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.